Risk factors, scoring systems, and interventions for alcohol relapse after liver transplantation for alcoholic liver disease
Jane Lim, Vinay Sundaram – 5 June 2018
Hepatic fibrosis: Avenues of investigation and clinical implications
Jessica E.S. Shay, James P. Hamilton – 5 June 2018
PRO (“The Window Is Open”): In patients with cirrhosis with prior variceal hemorrhage and ascites, the clinical benefits of nonselective beta‐blockers outweigh the risks and should be prescribed
Danielle Tholey, Nitzan Roth, Thomas Schiano – 5 June 2018
Imaging of abnormal liver function tests
Saivenkat H. Vagvala, Stacy D. O'Connor – 5 June 2018
Treatment of the extrahepatic manifestations of chronic hepatitis C infection
Karn Wijarnpreecha, Wisit Cheungpasitporn, Surakit Pungpapong, Kiran R. Nakkala – 5 June 2018
Issue Information
1 June 2018
Hepatitis B Virus–Upregulated LNC‐HUR1 Promotes Cell Proliferation and Tumorigenesis by Blocking p53 Activity
Ningning Liu, Qi Liu, Xiaohai Yang, Fang Zhang, Xinda Li, Yuanwu Ma, Feifei Guan, Xin Zhao, Zhiwei Li, Lianfeng Zhang, Xin Ye – 23 May 2018 – Recent studies have indicated that a number of long noncoding RNAs (lncRNAs) are dysregulated in hepatocellular carcinoma, while their aberrant expressions are associated with tumorigenesis and poor prognosis. To identify hepatitis B virus (HBV)‐related lncRNAs, we used RNA deep sequencing to quantify the abundances of lncRNAs in HepG2 cells and HBV transgenic HepG2‐4D14 cells.
Human Leukocyte Antigen F Locus Adjacent Transcript 10 Overexpression Disturbs WISP1 Protein and mRNA Expression to Promote Hepatocellular Carcinoma Progression
Jinlong Yan, Jun Lei, Leifeng Chen, Huan Deng, Dingxiang Dong, Tao Jin, Xiuxia Liu, Rongfa Yuan, Yumin Qiu, Jin Ge, Xiaogang Peng, Jianghua Shao – 23 May 2018 – Recently, studies on transcriptome–proteome relationships have revealed mRNA/protein expression discordance for certain genes and speculated that protein posttranslational modification (PTM) may be involved. However, there is currently no evidence to support this hypothesis.
Acetyl‐CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents
Leigh Goedeke, Jamie Bates, Daniel F. Vatner, Rachel J. Perry, Ting Wang, Ricardo Ramirez, Li Li, Matthew W. Ellis, Dongyan Zhang, Kari E. Wong, Carine Beysen, Gary W. Cline, Adrian S. Ray, Gerald I. Shulman – 23 May 2018 – Pharmacologic inhibition of acetyl‐CoA carboxylase (ACC) enzymes, ACC1 and ACC2, offers an attractive therapeutic strategy for nonalcoholic fatty liver disease (NAFLD) through simultaneous inhibition of fatty acid synthesis and stimulation of fatty acid oxidation.
Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial
Amardeep Khanna, Laura Jopson, Denise Howel, Andrew Bryant, Andrew Blamire, Julia L. Newton, David E. Jones – 23 May 2018 – Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. Half of patients experience debilitating fatigue, which is currently untreatable. Previous studies have shown muscle bioenergetic abnormalities in PBC, including increased muscle acidosis with exercise linked to the antimitochondrial antibody (AMA) diagnostic of the disease, and reduced anaerobic threshold.